IMV Année d'introduction en bourse
Quel est le Année d'introduction en bourse de IMV?
Le Année d'introduction en bourse de IMV, Inc. est 2012
Quelle est la définition de Année d'introduction en bourse?
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Année d'introduction en bourse des entreprises dans Health Care secteur sur TSX par rapport à IMV
Que fait IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Entreprises avec année d'introduction en bourse similaire à IMV
- American Century ETF Trust a Année d'introduction en bourse de 2011
- Sino Harbour a Année d'introduction en bourse de 2011
- Horizons Gold Prod Equty Cvrd C a Année d'introduction en bourse de 2011
- HFX a Année d'introduction en bourse de 2011
- Dark Horse Resources a Année d'introduction en bourse de 2011
- Om Metals Infraprojects a Année d'introduction en bourse de 2011
- IMV a Année d'introduction en bourse de 2012
- Evertec Inc a Année d'introduction en bourse de 2013
- Virtus Health a Année d'introduction en bourse de 2013
- Antero Resources Corp a Année d'introduction en bourse de 2013
- Murphy USA Inc a Année d'introduction en bourse de 2013
- Kodal Minerals Plc a Année d'introduction en bourse de 2013
- Agios Pharmaceuticals Inc a Année d'introduction en bourse de 2013